234 related articles for article (PubMed ID: 35405784)
21. [Clinic Outcome of Allogeneic Stem Cell Transplantation in 45 Patients with MDS].
Wang LJ; Liu MJ; Zhao XL; Ding J; Jing Y; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):502-9. PubMed ID: 27151019
[TBL] [Abstract][Full Text] [Related]
22. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
23. [Outcomes and prognostic factors of myelodysplastic syndrome patients with allogeneic hematopoietic stem cell transplantation].
Liu ZX; Lyu MN; Wang QQ; Zhai WH; Pang AM; Ma QL; Yang DL; He Y; Zhang RL; Huang Y; Wei JL; Feng SZ; Jiang EL; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):484-489. PubMed ID: 31340621
[No Abstract] [Full Text] [Related]
24. Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome.
Alessandrino EP; Porta MG; Malcovati L; Jackson CH; Pascutto C; Bacigalupo A; Teresa van Lint M; Falda M; Bernardi M; Onida F; Guidi S; Iori AP; Cerretti R; Marenco P; Pioltelli P; Angelucci E; Oneto R; Ripamonti F; Rambaldi A; Bosi A; Cazzola M;
Am J Hematol; 2013 Jul; 88(7):581-8. PubMed ID: 23606215
[TBL] [Abstract][Full Text] [Related]
25. Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party.
Scheid C; de Wreede L; van Biezen A; Koenecke C; Göhring G; Volin L; Maertens J; Finke J; Passweg J; Beelen D; Cornelissen JJ; Itälä-Remes M; Chevallier P; Russell N; Petersen E; Milpied N; Richard Espiga C; Peniket A; Sierra J; Mufti G; Crawley C; Veelken JH; Ljungman P; Cahn JY; Alessandrino EP; de Witte T; Robin M; Kröger N
Bone Marrow Transplant; 2017 Nov; 52(11):1519-1525. PubMed ID: 28892084
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of new IPSS-Molecular model and comparison of different prognostic systems in patients with myelodysplastic syndrome.
Ma J; Gu Y; Wei Y; Wang X; Wang P; Song C; Ge Z
Blood Sci; 2023 Jul; 5(3):187-195. PubMed ID: 37546714
[TBL] [Abstract][Full Text] [Related]
27. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
Alessandrino EP; Della Porta MG; Bacigalupo A; Van Lint MT; Falda M; Onida F; Bernardi M; Iori AP; Rambaldi A; Cerretti R; Marenco P; Pioltelli P; Malcovati L; Pascutto C; Oneto R; Fanin R; Bosi A;
Blood; 2008 Aug; 112(3):895-902. PubMed ID: 18497321
[TBL] [Abstract][Full Text] [Related]
28. [Survival efficacy of MDS/AML patients with TP53 abnormal received allogeneic hematopoietic stem cell transplantation].
Feng D; Wang MY; Liu J; Zhang HX; Chen X; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):222-229. PubMed ID: 37356984
[No Abstract] [Full Text] [Related]
29. Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome.
Ustun C; Trottier BJ; Sachs Z; DeFor TE; Shune L; Courville EL; Holtan SG; Dolan M; Weisdorf DJ; Warlick ED
Biol Blood Marrow Transplant; 2015 May; 21(5):866-72. PubMed ID: 25620751
[TBL] [Abstract][Full Text] [Related]
30. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.
Zeidan AM; Sekeres MA; Garcia-Manero G; Steensma DP; Zell K; Barnard J; Ali NA; Zimmerman C; Roboz G; DeZern A; Nazha A; Jabbour E; Kantarjian H; Gore SD; Maciejewski JP; List A; Komrokji R;
Leukemia; 2016 Mar; 30(3):649-57. PubMed ID: 26464171
[TBL] [Abstract][Full Text] [Related]
31. Upfront transplantation may have better outcomes than pretransplant cytoreductive therapy for treating patients with MDS-EB-1 or MDS-EB-2.
Chen Y; Huang F; Xuan L; Zhang Y; Fan Z; Xu N; Zhao K; Xu J; Liu H; Shi P; Wang Z; Sun J; Zheng W; Dai M; Liu Q
Int J Cancer; 2021 Sep; 149(5):1109-1120. PubMed ID: 33899230
[TBL] [Abstract][Full Text] [Related]
32. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.
Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
Br J Haematol; 2018 Jun; 181(5):614-627. PubMed ID: 29707769
[TBL] [Abstract][Full Text] [Related]
33. Prognostic evaluation of ALIP and CD34 immunostaining in IPSS-R subgroups of myelodysplastic syndromes.
Xiong B; Nie Y; Tang Z; Xue M; Zuo X
Pathology; 2017 Aug; 49(5):526-533. PubMed ID: 28669578
[TBL] [Abstract][Full Text] [Related]
34. Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients.
Hiwase DK; Singhal D; Strupp C; Chhetri R; Kutyna MM; Wee LA; Harrison PB; Nath SV; Wickham N; Hui CH; Gray JX; Bardy P; Ross DM; Lewis ID; Reynolds J; To LB; Germing U
Am J Hematol; 2017 Jun; 92(6):508-514. PubMed ID: 28247421
[TBL] [Abstract][Full Text] [Related]
35. European Group for Blood and Marrow Transplantation score correlates with outcomes of older patients undergoing allogeneic hematopoietic stem cell transplantation.
Chien SH; Liu YC; Liu CJ; Ko PS; Wang HY; Hsiao LT; Lin JS; Chiou TJ; Liu CY; Gau JP
J Chin Med Assoc; 2020 Mar; 83(3):238-244. PubMed ID: 31904659
[TBL] [Abstract][Full Text] [Related]
36. Maximizing the benefit of allogeneic stem cell transplantation in myelodysplastic syndromes.
Kröger N
Semin Hematol; 2017 Jul; 54(3):154-158. PubMed ID: 28958289
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Upfront Transplantation and Pretransplant Cytoreductive Therapy for Advanced Myelodysplastic Syndrome.
Wang H; Li Y; Xu Q; Zhou W; Yin C; Wang R; Wang M; Xu Y; Li Y; Yu L
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):631-640. PubMed ID: 34074612
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy and Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Monocytic Leukemia Patients].
Pan WY; Li KX; Wu SJ; Zheng YL; Deng L; Huang R; Tu SF; Song CY; Li YH; Huang YX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1859-1866. PubMed ID: 33283711
[TBL] [Abstract][Full Text] [Related]
39. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients.
Yang YT; Hou HA; Liu CY; Lin CC; Chou WC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Kuo YY; Huang SY; Ko BS; Chen CY; Hsu SC; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Sep; 89(9):E142-9. PubMed ID: 24845799
[TBL] [Abstract][Full Text] [Related]
40. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
